Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Peringkat dalam Saham #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Harga Saham
$0.15
Kapitalisasi Pasar
$4.96M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan Intellipharmaceutics International Inc. (IPCIF)

Kategori

Rasio P/E untuk Intellipharmaceutics International Inc. (IPCIF)
Rasio P/E per March 2026 TTM: -1.72
Menurut laporan keuangan dan harga saham terbaru dari Intellipharmaceutics International Inc., rasio P/E saat ini (TTM) adalah -1.72. Pada akhir 2021, perusahaan memiliki rasio P/E sebesar -1.22.
Riwayat rasio P/E untuk Intellipharmaceutics International Inc. dari 1999 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
2026 (TTM) -1.72 114.53%
2022 -0.80 -34.41%
2021 -1.22 105.11%
2020 -0.60 -37.64%
2019 -0.95 734.44%
2018 -0.11 -96.12%
2017 -2.95 -59.83%
2016 -7.34 9.41%
2015 -6.71 -61.01%
2014 -17.21 155.32%
2013 -6.74 -0.93%
2012 -6.81 -29.45%
2011 -9.65 93.02%
2010 -5.00 0.00%
2009 0.00 -100.00%
2008 -8.65 152.51%
2007 -3.43 353.05%
2006 -0.76 51.93%
2005 -0.50 -9.04%
2004 -0.55 -56.22%
2003 -1.25 -35.54%
2002 -1.94 -20.97%
2001 -2.45 -27.10%
2000 -3.37 24.41%
1999 -2.71 0.00%
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
10.72 -724.47%
DK
30.14 -1,856.44%
US
17.03 -1,092.58%
US
30.44 -1,873.60%
BE
38.30 -2,331.79%
NL
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.